SAB Biotherapeutics, Inc.

Big Cypress Acquisition Corp. (Nasdaq: BCYP) was a blank-check company that completed its initial public offering in 2021, targeting opportunities in the healthcare and life sciences sector. In June 2021, BCYP announced a definitive business combination agreement with SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company developing fully human polyclonal antibodies through a proprietary platform utilizing genetically engineered cattle. SAB's pipeline has focused on infectious diseases and other serious medical conditions within the biotech and pharma space. The transaction has since closed, concluding BCYP's life as a standalone SPAC. Sign up for SpacDesk to access the full data profile on Big Cypress Acquisition Corp. and thousands of other SPAC transactions.

SPAC Counterparty (1)